Goldman Sachs Group Inc. grew its position in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 45.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 330,655 shares of the specialty pharmaceutical company’s stock after purchasing an additional 103,534 shares during the period. Goldman Sachs Group Inc. owned 0.63% of SciClone Pharmaceuticals worth $3,637,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the business. State of Alaska Department of Revenue raised its stake in shares of SciClone Pharmaceuticals by 78.9% during the second quarter. State of Alaska Department of Revenue now owns 10,213 shares of the specialty pharmaceutical company’s stock valued at $112,000 after purchasing an additional 4,503 shares during the period. Profund Advisors LLC bought a new stake in shares of SciClone Pharmaceuticals in the second quarter worth $113,000. Municipal Employees Retirement System of Michigan increased its stake in shares of SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 310 shares during the last quarter. Mason Street Advisors LLC increased its stake in shares of SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 881 shares during the last quarter. Finally, OppenheimerFunds Inc. increased its stake in SciClone Pharmaceuticals by 29.9% during the first quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 3,065 shares during the last quarter. 72.80% of the stock is currently owned by institutional investors.
SciClone Pharmaceuticals, Inc. (SCLN) remained flat at $$11.15 during mid-day trading on Friday. 2,224,600 shares of the company’s stock were exchanged, compared to its average volume of 444,833. SciClone Pharmaceuticals, Inc. has a 1-year low of $8.55 and a 1-year high of $11.43.
SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 27.39% and a return on equity of 20.24%. The company had revenue of $44.52 million during the quarter.
In other SciClone Pharmaceuticals news, CEO Hong Zhao sold 30,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $330,000.00. Following the sale, the chief executive officer now directly owns 30,000 shares in the company, valued at $330,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Lan Xie sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total transaction of $110,000.00. Following the completion of the sale, the vice president now owns 10,000 shares in the company, valued at $110,000. The disclosure for this sale can be found here. Corporate insiders own 5.16% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Goldman Sachs Group Inc. Purchases 103,534 Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/11/sciclone-pharmaceuticals-inc-scln-shares-bought-by-goldman-sachs-group-inc.html.
SciClone Pharmaceuticals Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.